Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas

Leukemia and Lymphoma

Volumn 33, Issue 1-2, 1999, Pages 155-160

  Lossos, Izidore S ^a   Paltiel, Ora ^a   Polliack, Aaron ^a,b  

^a HEBREW UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Fludarabine; Fludarabine + cyclophosphamide; Intermediate grade; Low grade; Lymphoma; Refractory; Relapsing lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BRAIN DISEASE; CANCER GRADING; CLINICAL ARTICLE; CLINICAL TRIAL; CONVULSION; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SALVAGE THERAPY; SOMNOLENCE; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 0033011668     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199909093737     Document Type: Article

References (16)

1. Horning SJ. Natural history of and therapy tor the indolent non-Hodgkin's lymphomas. Semin Oncol 1993:20:75-88.
2. Fisher RI, Gaynor ER, Dahlberg S et al. Combination of standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993:328: 1002-1006.
3. Longo DT, Mauch P, DeVita VT, Urba WJ, Jatte ES. Lymphocylic lymphoma. In: Cancer: Principles and Practice of Oncology. DeVita VT, Hellman S and Rosenberg SA, eds. Philadelphia: Lippincott, 1993, pp, 1859-1927.
4. Plunkiett W, Gandhi V, Huang P et al. Fludarabine: Pharmacokinetics, mechanism of action, and rationales for combination therapies. Semin Oncol 1993 ; 20(Suppl 7):2-12.
5. Keating MJ, Estey E, O'Brien S, Kantarjian H, Robertson LE, Plunkett W. Clinical experience with fludarabine in leukaemia. Drugs 1994;47(Suppl 6):39-49.
6. Redman JR, Cabanillas F, Velasquez WS et al. Phase II trial of fludarabine phosphate in lymphomas: An effective new agent in low-grade lymphoma. J Clin Oncol 1992:790-794.
7. Hochster HS, Kim K, Green MD et al., Activity of fludarabine in previously treated non-Hodgkin's low grade lymphoma: Results of an Eastern Cooperative Oncology Group study. J Clin Oncol 1992; 10:28-32.
8. Yang S, Huang P, Plunkett W, Becker F, Chun J. Dual mode of inhibition of purified DNA ligase I from human cells by 9-ß-d-arabinofuranosyl-2-fluoroadenine triphosphate. J Biol Chem 1992;267:2345-2349.
9. Adkins JC, Peters DH, Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997;53:1005-1037.
10. Hochster H, Oken M, Bennett J et al. Efficacy of cyclophosphamide and fludarabine as first line therapy of low grade non-Hodgkin's lymphoma - ECOG 1491. (Abstract) Blood 1994;84(Suppl 1):383a.
11. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
12. Zinzani PL, Lauria F, Rondelli D et al. Fludarabine: An active agent in the treatment of previously treated and untreated low-grade non-Hodgkin's lymphoma. Ann Oncol 1993;4:575-578.
13. Stewart AK, Brandwein JM, Sutcliffe SB, Scott JG, Keating A. Mini-beam as salvage chemotherapy for refractory Hodgkin's disease and non-Hodgkin's lymphoma. Leuk Lymphoma 1991;5:111-115.
14. Velasquez WS, Cabanillas F, Salvador P et al. Effective salvage therapy for lymphoma with cisplatin in combination with high dose Ara-C and dexamethasone (DHAP). Blood 1988 ;71 :117-122.
15. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995:13:2431-2448.
16. Byrd JC, Hargis JB, Kester KE, Hospenthal DR, Knutson SW, Diehl LF. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am J Hemat 1995;49:135-142.